Developing Therapies for Which There Are No Cures
Born of the goal of creating life-changing treatments based on the immunomodulatory benefits of stem cells, PrimeGen is turning its goal into reality as we prepare our stemXcell™ platform for clinical trials in the USA and China
Since our founding in 2002, we’ve grown from a small R&D operation in Southern California to a multinational clinical cell treatment provider with a robust pipeline of products targeting several inflammatory diseases.
Based on a foundation of research spanning two decades and reinforced by numerous proprietary processes and patented technologies, our stemXcell platform focuses our therapies on treating inflammation, the root of most diseases, giving PrimeGen Global a distinct advantage over other cell therapy companies. Starting with potent, high-quality stem cells developed in line with strict United States Food and Drug Administration’s GMP guidelines, we apply our patented techniques to jumpstart the immunomodulatory properties of our cells prior to patient administration. This process allows us to focus the cells on serving a specific function in the treatment of different disease types.
Today, we’re in the process of preparing our allogeneic stemXcell treatments for clinical trials in the USA and in China, where they will be used to treat acute and chronic liver disease.
With a long history of innovation and stem cell industry firsts, our scalable and flexible stemXcell treatment platform and growing manufacturing and clinical capabilities, PrimeGen Global is positioned to make cell therapies a mainstay of modern medicine.
Chairman of the Board, Founder
After decades in the computer and electronics industries, and founded publicly traded companies, such as Fortune 500 AST Research Inc. and audio giant SRS Labs, Inc. in the U.S., Thomas Yuen, a successful serial entrepreneur, embarked on a personal battle with his chronic kidney disease with his long tenure in the exploration and research of stem cells in human therapeutic applications.
PrimeGen Biotech was established in 2002 in Irvine, California, with the aim to advance the domain of stem cell research and applications towards the improvement of quality of life for people suffering from chronic or debilitating diseases.
AWARDS & ACCOMPLISHMENTS
1986 to present | UC Irvine, California, USA
Distinguished Alumnus Award
Outstanding Engineering Alumni Award
UC Irvine Medal
UC Irvine Foundation Board of Trustees
UC Irvine Institute for Innovation Founding Board
1991 | Beijing, China – Honorary Minzu University professor
2012 | TechAmerica, Orange County, California – Lifetime Achievement Award
2015 | Providence Speech & Hearing Center, Orange County, California – Board member
Dr. Raymond Tong M.D., Ph.D, MBA
Chief Executive Officer, PrimeGen Global, Director
Dr. Tong is a medical professional turned seasoned entrepreneur with over 30 years of experience in the healthcare industry across Asia and North America. After founding a successful chain of twelve medical clinics in Toronto with annual revenues of USD 10 million, Dr. Tong returned to Hong Kong in 1988, and spent over ten years in senior management roles with multinational companies in the medical and pharmaceutical industries in Hong Kong and China.
Dr. Tong then joined CITIC Pacific Limited in Hong Kong for over nine years, and was actively involved with all of the Group’s investment projects in the healthcare sector.
In 2009, Dr Tong established his personal investment and consultancy business in the healthcare and manufacturing industries in the Greater China region.
Dr. Shi Yu Fang, Ph.D.
Chief Science Officer, Director
Trained as an immunologist, Dr. Shi decided to explore the world of stem cells 15 years ago. Dr. Shi obtained his Veterinarian Degree from China and then went to Canada for his M.Sc., Ph.D. and postdoctoral training in immunology. He moved to USA and first worked on T cell apoptosis and then focused on stem cells development. His recent most important discovery is the immune-modulatory nature of stem cells, which is now considered as one of the major functions of stem cells. He was also one of the first to use cytokines activation as a method to enhance the immunomodulatory effects of stem cells.
Dr. Shi relocated to China in 2008 and since then continue his contributions to the mainstream stem cell research field.
Mr. Wai Szeto
Chief Operating Officer, Executive Vice President, Director
Mr. Wai Szeto is an accomplished business development strategist, who is well versed in the formation of U.S. and international joint ventures. Together with his strong experience in the development of global supply chains and manufacturing facilities, Mr. Szeto has assisted some of the largest companies in the world to generate billions in revenues.
Prior to becoming COO of PrimeGen, Mr. Szeto held senior management roles with the China and technology subsidiaries of Kingston Technology- one of the largest semiconductor memory products manufacturers in the world. Before Kingston, Mr. Szeto served with Mr. Tom Yuen, as Vice President of Global Operations of AST Research, a Fortune 500 company and one of the world’s leading, personal computer manufacturers at the time. He managed engineering groups that created leading-edge personal computers, developed global manufacturing and supply chain networks, cultivated strategic supplier relationships, and oversaw Asia Pacific marketing and sales.
Mr. Jim McNiel
Chief Executive Officer, PrimeGen US, Director
Mr. McNiel is a seasoned senior executive with more than 30 years of experience in high technology and private equity. He began his career as a software engineer for Lucasfilm Ltd. And later left engineering to enter marketing and product management at AST Research/Computer. After rising to the role of senior director of advanced products at AST Mr. McNiel moved to New York to start Cheyenne Software. Seven years later Cheyenne was sold to Computer Associates for $1.3 billion in cash. Mr. McNiel then joined Pequot Capital and served as a General Partner and led the firm’s software investment practice for nine years. Working on both coasts Mr. McNiel made investments in Netgear, Netegrity and other successful technology firms.
Mr. McNiel has served as the Chief Marketing Officer for public company NETSCOUT and CEO for FalconStor and Fifth Generation Software. Mr. McNiel has served on more than 20 public and private boards and was a board member and trustee of the Foundation Fighting Blindness and the Clinical Research Institute. Mr. McNiel studied business at the Wharton School and Finance at MIT Sloane and has received multiple awards from FastCompany, Cannes Lions, AdWeek, OneCentre and others.
Mr. McNiel was the creator and executive producer for the critically acclaimed Werner Herzog documentary Lo and Behold: Reveries of the Connected World.
Mr. Steve Gershick, CPA, CGMA
Chief Financial Officer, Director
Steve Gershick has substantial, hands-on experience in operations, business planning and corporate finance, debt and equity-based seed, venture, institutional, and PIPE financing. Interfacing between the various levels of the investment community in the U.S. with both private and public companies, Mr. Gershick is well versed in strategic alliance formation and management, mergers & acquisitions, and global technology licensing.
After graduating in Business Administration from California State University in 1977, Mr. Gershick obtained his Certified Public Accountant and Chartered Global Management Accountant accreditations. He joined PrimeGen as COO/CFO from 2004-2008, and had been a member of the Board of Managers and Chief Financial Officer since 2014.
Mr. Gershick has also served as CFO and COO for several private and public companies in technology, biotechnology and life sciences, including NuRX Pharmaceuticals, a clinical stage biopharmaceutical company, and led the health services diligence and finance teams for a boutique merchant banking firm, including a USD$100 million Special Purpose Acquisition Company funded by Citigroup.
Dr. Wang Ying M.D., Ph.D.
A Note From Our Chairman
During the winter of 1980 my kidneys failed, and I was informed that I would require dialysis for the rest of my life. I also learned that my condition was hereditary, and that my children could face similar issues in their future. This dire outlook inspired me to make it my life’s work to identify new therapies for the disease, as well as a broad array of other chronic diseases. After many years of research and reaching out to numerous experts on possible treatments, I learned of stem cells and their exciting potential.
In 2002, the PrimeGen story began. From its inception, PrimeGen has been at the forefront of numerous cell therapy breakthroughs, and led in pioneering roles in many of the exciting cell therapy applications either in use or being explored today, including adult reprogramming of adult multipotent stem cells, fertility preservation, the derivation and use of iPSCs, MSCs, and more.
At PrimeGen, we continue to maintain a leadership role in the cellular therapy industry and are working diligently toward our vision of making cell therapies a viable treatment for countless diseases in the years ahead. We are committed to building on our performance in areas where we are strong, while persevering in other areas where we see opportunities for improving patient outcomes.